BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1169 related articles for article (PubMed ID: 21090814)

  • 1. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
    Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
    J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
    Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
    Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and characterization of a substrate selective p38alpha inhibitor.
    Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
    Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-driven HtL: design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity.
    Stocks MJ; Barber S; Ford R; Leroux F; St-Gallay S; Teague S; Xue Y
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3459-62. PubMed ID: 15950471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery and initial optimisation of pyrrole-2-carboxamides as inhibitors of p38alpha MAP kinase.
    Down K; Bamborough P; Alder C; Campbell A; Christopher JA; Gerelle M; Ludbrook S; Mallett D; Mellor G; Miller DD; Pearson R; Ray K; Solanke Y; Somers D
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3936-40. PubMed ID: 20570148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
    Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.
    Szczepankiewicz BG; Kosogof C; Nelson LT; Liu G; Liu B; Zhao H; Serby MD; Xin Z; Liu M; Gum RJ; Haasch DL; Wang S; Clampit JE; Johnson EF; Lubben TH; Stashko MA; Olejniczak ET; Sun C; Dorwin SA; Haskins K; Abad-Zapatero C; Fry EH; Hutchins CW; Sham HL; Rondinone CM; Trevillyan JM
    J Med Chem; 2006 Jun; 49(12):3563-80. PubMed ID: 16759099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation.
    Nickischer D; Laethem C; Trask OJ; Williams RG; Kandasamy R; Johnston PA; Johnston PA
    Methods Enzymol; 2006; 414():389-418. PubMed ID: 17110204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of bi-thiazole-2,2'-diamines as kinase inhibitory scaffolds.
    Ngoei KR; Ng DC; Gooley PR; Fairlie DP; Stoermer MJ; Bogoyevitch MA
    Biochim Biophys Acta; 2013 Jun; 1834(6):1077-88. PubMed ID: 23410953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode.
    Angell RM; Bamborough P; Cleasby A; Cockerill SG; Jones KL; Mooney CJ; Somers DO; Walker AL
    Bioorg Med Chem Lett; 2008 Jan; 18(1):318-23. PubMed ID: 18006306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase.
    Laufer S; Lehmann F
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1461-4. PubMed ID: 19195885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.
    Cumming JG; Debreczeni JÉ; Edfeldt F; Evertsson E; Harrison M; Holdgate GA; James MJ; Lamont SG; Oldham K; Sullivan JE; Wells SL
    J Med Chem; 2015 Jan; 58(1):278-93. PubMed ID: 25255283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Displacement assay for the detection of stabilizers of inactive kinase conformations.
    Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
    J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha.
    Patel SB; Cameron PM; O'Keefe SJ; Frantz-Wattley B; Thompson J; O'Neill EA; Tennis T; Liu L; Becker JW; Scapin G
    Acta Crystallogr D Biol Crystallogr; 2009 Aug; 65(Pt 8):777-85. PubMed ID: 19622861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence, structure, and active site analyses of p38 MAP kinase: exploiting DFG-out conformation as a strategy to design new type II leads.
    Badrinarayan P; Sastry GN
    J Chem Inf Model; 2011 Jan; 51(1):115-29. PubMed ID: 21141877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.
    Frembgen-Kesner T; Elcock AH
    J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha.
    Simard JR; Grütter C; Pawar V; Aust B; Wolf A; Rabiller M; Wulfert S; Robubi A; Klüter S; Ottmann C; Rauh D
    J Am Chem Soc; 2009 Dec; 131(51):18478-88. PubMed ID: 19950957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors.
    Laufer SA; Domeyer DM; Scior TR; Albrecht W; Hauser DR
    J Med Chem; 2005 Feb; 48(3):710-22. PubMed ID: 15689155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.